Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695065 | 0.85 | MEN1 (0.68) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL696258 | 0.84 | BCHE (0.68) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL4692148 | 0.84 | ALDH1A1 (0.42) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL736332 | 0.83 | MEN1 (0.54) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL56141 | 0.80 | P2RX7 (0.43) | MEN1KMT2APOLBGAABCHE | |
| Hydrochloric Acid SCHEMBL3354807 | 0.78 | MEN1 (0.42) | MEN1KMT2APOLBGAABCHE | |
| SCHEMBL22910535 | 0.78 | SLC6A4 (0.49) | POLBALDH1A1GAABCHEACHE | |
| SCHEMBL6110591 | 0.77 | BCHE (0.51) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL27091860 | 0.77 | MEN1 (0.65) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL736962 | 0.77 | GLA (0.53) | MEN1KMT2APOLBALDH1A1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | claimed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| WO-2006021401-A2 | BICYLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021399-A2 | AZABICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| EP-1622907-A1 | AZABICYCLONONENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1622906-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1622685-A1 | 9-AZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1622901-A1 | TROPANE DERIVATIVES AND THEIR USE AS ACE INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096366-A1 | 9-AZABICYCLO’3.3.1!NON-6-EE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096799-A1 | TROPANE DERIVATIVES AND THEIR USE AS ACE INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096804-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096803-A1 | AZABICYCLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | MEN1 1386/4885KMT2A 4717/4885POLB 3919/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | MEN1 2812/4885KMT2A 2850/4885POLB 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.